Laminate Medical Technologies, a Tel Aviv, Israel-based developer of the VasQ™ External Vascular Support Device for arteriovenous fistulas in patients requiring dialysis, received an investment from Valiance Asset Management.
Valiance made the investment through its Luxembourg domiciled Life Sciences Global Investment Fund, in addition to the investment announced earlier this year by Asahi Kasei Medical, a large manufacturer of dialysis equipment, Tal Capital, Mickey Boodaei, Shai Agassi, Yuval Tal and Meir Barel.
In addition, following the capital raise, Jose Calle Gordo, a Managing Partner at Valiance, will join Laminate as a member of the Board of Directors.
Founded in 2012 by Tammy Gilon, who serves as CEO of the company, and Dr. Eyal Orion, Laminate Medical Technologies develops the VasQ™ External Vascular Support Device a dual-component, nitinol external support for the arteriovenous anastomosis of hemodialysis patients. The device, placed around the artery-vein surgical connection, provides structural support needed to ensure maturation of the fistula into a usable access for dialysis.
The device, placed around the artery-vein surgical connection, provides structural support necessary to ensure maturation of the fistula into a usable access for dialysis.
VasQ has already received European CE approval and is commercialized locally by means of a broad network of distributors in Italy, Switzerland, and Austria and is in use in hundreds of hospitals across Europe with impressive results.
Existing investors include the Chinese pharma company Haisco, Nava and Yehuda Zissapel, Zohar Gilon, Eri Steimatzky, Henit Vitos, and Ari Rabad.